Patent · US Active

NK cell engaging antibody fusion constructs

US11001633B2 · kind B2 · utility

0Cited by

1References

14Claims

0Family size

Assignee

AFFIMED GMBH · DE

Inventors

Michael Tesar · Heidelberg, DE
Kristina Ellwanger · Heidelberg, DE
Ivica Fucek · Hattersheim, DE
Uwe Reusch · Maikammer, DE
Thorsten Ross · Edingen-Neckarhausen, DE
Joachim Koch · Heidelberg, DE
Erich Rajkovic · Schriesheim, DE
Martin Treder · Heidelberg, DE

Key dates

Filing date	Dec 13, 2019
Grant date	May 11, 2021
Priority date	—
Expiry date	Dec 13, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07K2317/92
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to multispecific antigen-binding proteins for engaging natural killer (NK) cells for triggering NK cell cytotoxicity by engaging the CD16A (FcγRIIIA) expressed on NK cells, wherein the antigen-binding protein comprises at least two CD16A antigen-binding moieties and at least a further target antigen-binding moiety. The CD16A antigen-binding moiety comprises light chain and heavy chain variable regions linked one after another in a polypeptide chain and the variable region at the N-terminus of the polypeptide chain comprising the CD16A antigen-binding moiety is a light chain variable region.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.